Details

Autor(en) / Beteiligte

• Zhang, G J
• Gong, X Y
• Qiu, S W
• Zhou, C L
• Liu, K Q
• Lin, D
• Liu, B C
• Wei, H
• Wei, S N
• Li, Y
• Gu, R X
• Gong, B F
• Liu, Y T
• Fang, Q Y
• Mi, Y C
• Wang, Y
• Wang, J X

Titel

Dasatinib combined with multi-agent chemotherapy regimen in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a prospective study from a single center

Ist Teil von

• Zhōnghuá xuèyèxué zázhì, 2021-02, Vol.42 (2), p.109-115

Ort / Verlag

China

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• This study evaluates the efficacy and safety of dasatinib combined with a multi-agent chemotherapy regimen of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) patients. This prospective, single-arm, and open clinical study enrolled 30 adult Ph(+) ALL patients who were newly diagnosed and treated from January 2016 to April 2018 in the center of this study. Standard induction chemotherapy was given for 4 weeks. However, dasatinib (100 mg/d) was continuously administered from day 8 until the end of the whole therapy in the induction therapy. Patients who are available for allogeneic or autologous stem cell transplantation (SCT) received transplantation when the disease was evaluated as complete remission. All 30 patients achieved hematological complete remission (HCR) after the induction chemotherapy, and 70.0% (21/30) of them achieved the accumulated molecular complete remission (MCR) . The patients were followed up with a median follow-up time of 37.8 months (32.0-46.6) . The 3 year ov